The FDA Drug Safety Communications posted on this web page are intended to provide important information to patients and health care professionals about new safety issues with the medicines they are taking or prescribing so they can make more informed decisions about treatment.
Widespread or long-term use of drugs by patients may uncover side effects not discovered during the clinical trials a drug company did to get FDA approval of the medicine. As a result, FDA physicians and scientists continue to monitor the safety of drugs after they are approved. When we learn information about a potential new safety issue, we review the data from available clinical trials or other studies, case reports, and medical literature. Based on what we find, we may require changes to the prescribing information or the patient Medication Guide. We may also release a Drug Safety Communication to alert patients and health care professionals about the issue.
You can get new safety information on medicines you’re prescribing or taking by signing up for email alerts about Drug Safety Communications on types of drugs or medical specialties of specific interest to you.
Current Drug Safety Communications
- 11/22/2022 FDA investigating risk of severe hypocalcemia in patients on dialysis receiving osteoporosis medicine Prolia (denosumab)
- 6/30/2022 FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)
- 6/1/2022 FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns
- 3/30/2022 FDA recommends thyroid monitoring in babies and young children who receive injections of iodine-containing contrast media for medical imaging
Previous Drug Safety Communications
Additional Resources For You
- Development & Approval Process (Drugs)
- How Drugs are Developed and Approved
- The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective
- Frequently Asked Questions about the FDA Drug Approval Process
- Think It Through: Managing the Benefits and Risks of Medicines
- CDER Conversation: CDER's Drug Safety Communications: Ensuring postmarket safety
- Drus@FDA: FDA-Approved Drugs